{"schema_version":"secwatch.filing_event.v1","accession":"0001531048-24-000050","form_type":"8-K","ticker":null,"cik":"0001531048","company_name":"Inari Medical, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.412873+00:00","generated_at":"2026-05-31T15:16:27.353402+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Inari Medical CFO Mitch Hill to retire Oct 1, succeeded by Kevin Strange","bullets":["Hill retires as CFO effective Oct 1, 2024; will stay in non-executive role through Jan 2, 2025 to assist transition.","Kevin Strange, current SVP Finance, Accounting, Strategy and BD, appointed new CFO effective Oct 1, 2024.","Strange compensation: $480k base salary, target bonus 60% of base, $250k RSU grant vesting over 4 years, $300k relocation bonus.","Strange has over 15 years med device finance experience; previously at Boston Scientific, Wells Fargo, and Medtronic.","Transition is orderly; Hill led IPO in May 2020 and developed Strange as successor."],"urls":{"canonical":"https://secwatch.observer/filing/0001531048-24-000050","json":"https://secwatch.observer/filing/0001531048-24-000050.json","markdown":"https://secwatch.observer/filing/0001531048-24-000050.md","text":"https://secwatch.observer/filing/0001531048-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/0001531048-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/nari-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:16:27.353402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79c7b39397","claim":"Kevin Strange was appointed as Chief Financial Officer at Inari Medical, Inc..","evidence_excerpt":"On July 24, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Kevin Strange as the Chief Financial Officer of the Company as of the Effective Date, succeeding Mr. Hill.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/0001531048-24-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c5e40b96e4","claim":"Mitch Hill departed as Chief Financial Officer at Inari Medical, Inc..","evidence_excerpt":"On July 24, 2024, Mitch Hill notified Inari Medical, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/0001531048-24-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}